Latest Capital Raise News

Powerhouse Ventures Limited reported a striking 348.8% jump in profit after tax to $1.82 million for FY25, driven by strategic acquisitions and a robust investment portfolio. The company’s first operating cash profit and growth in net tangible assets signal a turning point in its transformation.

SportsHero Limited reported a 189% revenue increase to AU$37,666 for FY25, driven by strategic partnerships across Southeast Asia, despite a continuing loss of nearly AU$2 million. The company secured major telco collaborations and expanded its gaming product footprint in Indonesia and the Philippines.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Janus Electric Holdings reported a steep 94% rise in net loss to $8.7 million for FY2025, impacted by a disruptive battery recall and significant restructuring costs. The company completed a reverse takeover, raised $8.8 million, and secured a $5 million MOU for African expansion, signaling a bold shift toward heavy transport electrification.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

Ovanti Limited’s FY2025 results reveal a modest revenue dip but a sharp 61% rise in net loss, driven by a significant impairment charge. The company’s capital base strengthened despite ongoing losses, with no dividends declared.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

RBR Group Limited reported an 88% plunge in revenue and a widening net loss for FY2025, impacted by political instability and LNG project delays in Mozambique. The company is investing in facility upgrades and workforce training to position itself for a market rebound.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.